Hospital
Bowling Green-Warren County Community Hospital Corporation
Bowling Green-Warren County Community Hospital Corporation was paid $8.82M by Medicaid between Jan 2018 and Nov 2024, across 136 billing codes. Its largest line is 99284, emergency room visit (serious) — 22% of everything it billed.
33Billing provider infoBOWLING GREEN-WARREN COUNTY COMMUNITY HOSPITAL CORPORATION
ALBANY, KY 42602
ALBANY, KY 42602
33aNPI1598125502assigned 03/03/2016
33bProvider typeCritical Access Hospital
28Total paid$8.82M
24GClaims238,276
24DCodes billed136
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Critical Access Hospital providers in Kentucky
Rank by total paid#13 of 16
Median peer was paid$11.73M
This provider vs. median0.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LAWLESS, MICHELE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 33,282 | $1.32M | |
| 2019 | 37,972 | $1.30M | |
| 2020 | 32,751 | $1.19M | |
| 2021 | 43,559 | $1.47M | |
| 2022 | 39,122 | $1.43M | |
| 2023 | 40,849 | $1.65M | |
| 2024incomplete | 10,741 | $469K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 22% | 9,346 | 7,419 | $1.93M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.9% | 3,852 | 2,443 | $877K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.7% | 5,309 | 4,731 | $770K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 8.1% | 1,970 | 1,518 | $713K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 5.0% | 1,162 | 719 | $441K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.5% | 10,387 | 1,813 | $309K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.4% | 1,362 | 924 | $300K |
| G0378 | Hospital observation service, per hour | 3.0% | 1,436 | 561 | $269K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.8% | 4,519 | 3,760 | $251K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.5% | 5,928 | 1,479 | $222K |
| 71046 | Radiologic examination, chest; 2 views | 2.4% | 4,026 | 2,953 | $215K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.0% | 9,537 | 4,883 | $178K |
124 more codes
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.9% | 9,095 | $170K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.8% | 2,274 | $158K |
| 71045 | Radiologic examination, chest; single view | 1.5% | 4,070 | $131K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.1% | 2,809 | $95K |
| 80053 | Comprehensive metabolic panel | <1% | 17,998 | $88K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 15,058 | $87K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,426 | $80K |
| 36415 | Collection of venous blood by venipuncture | <1% | 14,374 | $72K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 6,647 | $69K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,009 | $66K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,018 | $61K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 4,998 | $53K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 514 | $50K |
| 82803 | <1% | 2,495 | $44K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,411 | $44K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 87 | $44K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 141 | $42K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,697 | $41K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,440 | $38K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,264 | $38K |
| J2704 | Injection, propofol, 10 mg | <1% | 2,384 | $32K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,115 | $31K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,309 | $30K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,586 | $30K |
| 83605 | <1% | 3,347 | $28K | |
| 84484 | <1% | 3,123 | $27K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,334 | $25K |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 1,383 | $25K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 495 | $24K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,589 | $24K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,874 | $22K |
| 82330 | <1% | 2,082 | $21K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 763 | $19K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 186 | $19K |
| 97162 | <1% | 410 | $18K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 37 | $18K |
| 83880 | <1% | 726 | $17K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 129 | $17K |
| 87430 | <1% | 1,242 | $17K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,620 | $17K |
| 80306 | <1% | 1,203 | $17K | |
| 82375 | <1% | 1,816 | $15K | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 1,022 | $15K |
| 84703 | <1% | 2,150 | $14K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 806 | $14K |
| 73610 | <1% | 150 | $14K | |
| 73562 | <1% | 153 | $13K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 992 | $12K |
| 83690 | <1% | 2,202 | $12K | |
| 72100 | <1% | 198 | $12K | |
| 71250 | <1% | 65 | $12K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 209 | $12K |
| 94664 | <1% | 1,315 | $11K | |
| 73030 | <1% | 132 | $11K | |
| 74018 | <1% | 118 | $10K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 41 | $9K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,897 | $9K |
| 83009 | <1% | 221 | $9K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 179 | $9K |
| 73130 | <1% | 89 | $9K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 693 | $8K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 90 | $8K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 38 | $8K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 633 | $8K |
| 85610 | <1% | 2,677 | $7K | |
| 73630 | <1% | 73 | $7K | |
| 82565 | <1% | 1,745 | $6K | |
| 84145 | <1% | 313 | $6K | |
| 80076 | <1% | 1,092 | $6K | |
| 87339 | <1% | 482 | $6K | |
| 84132 | <1% | 1,648 | $5K | |
| 84295 | <1% | 1,590 | $5K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 513 | $5K |
| 82435 | <1% | 1,588 | $5K | |
| 81001 | <1% | 2,808 | $5K | |
| 83050 | <1% | 832 | $5K | |
| 87400 | <1% | 385 | $5K | |
| 78227 | <1% | 14 | $5K | |
| 82947 | <1% | 1,906 | $4K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 15 | $4K |
| 87186 | <1% | 617 | $4K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 305 | $4K |
| 85730 | <1% | 934 | $4K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 414 | $4K |
| 81003 | <1% | 1,784 | $3K | |
| 84520 | <1% | 997 | $3K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 242 | $3K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 13 | $3K |
| 81015 | <1% | 1,011 | $2K | |
| 97010 | <1% | 289 | $2K | |
| 93226 | <1% | 20 | $2K | |
| 87040 | <1% | 259 | $2K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 92 | $2K |
| 80047 | <1% | 174 | $2K | |
| 76642 | <1% | 16 | $2K | |
| 83735 | <1% | 391 | $2K | |
| 87420 | <1% | 122 | $2K | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 57 | $1K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 118 | $1K |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 118 | $1K |
| 82948 | <1% | 171 | $1K | |
| 80061 | Lipid panel | <1% | 144 | $1K |
| 87070 | <1% | 213 | $1K | |
| 97014 | <1% | 42 | $1K | |
| 87634 | <1% | 29 | $1K | |
| 77080 | <1% | 20 | $866.82 | |
| 82150 | <1% | 188 | $842.39 | |
| 85651 | <1% | 226 | $715.68 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 152 | $691.17 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 95 | $672.54 |
| 82553 | <1% | 63 | $664.81 | |
| 85379 | <1% | 86 | $597.27 | |
| 82550 | <1% | 92 | $578.57 | |
| 94761 | <1% | 20 | $421.91 | |
| 82607 | <1% | 43 | $407.16 | |
| 36416 | <1% | 172 | $356.29 | |
| 87807 | <1% | 29 | $340.60 | |
| 87077 | <1% | 16 | $145.44 | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 40 | $100.30 |
| 85652 | <1% | 43 | $97.61 | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 3,864 | $95.51 |
| 86308 | <1% | 18 | $72.52 | |
| 85018 | <1% | 36 | $39.81 | |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 15 | $19.40 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLAWLESS, MICHELE (EXECUTIVE VICE PRESIDENT & CFO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.